Feb 2021 $10 M No. 5 $10 to $50 million 6
Cancer Genetics Inc.: Raise no. 5, Feb 2021 × Investors in this round 6 investors had bought by the notice of Feb 3, 2021: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cancer Genetics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $775,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice John A. Roberts · Executive Officer Edmund Cannon · Director Franklyn G. Prendergast · Director Geoffrey G. Harris · Director Howard G. McLeod · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in CA, IL, NV, NY Remarks in the notice On fees: “Excludes the value of up to 165,517 warrants issued to the Placement Agent exercisable at $4.5313 per share.”On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”Signed by John A. Roberts, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Feb 3, 2021. Read the notice at the SEC .
equity, options SEC Mar 2017 $6 M No. 4 $2 to $10 million 3
Cancer Genetics Inc.: Raise no. 4, Mar 2017 × Investors in this round 3 investors had bought by the notice of Mar 27, 2017: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cancer Genetics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice John A. Roberts · Executive Officer Panna L. Sharma · Executive Officer, Director Edmund L. Cannon · Director Franklyn G. Prendergast · Director Geoffrey J. Harris · Director Howard J. McLeod · Director John L. Pappajohn · Director Michael J. Welsh · Director Raju S.K. Chaganti · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Excludes proceeds to be received from exercise of warrants.”On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”Signed by John A. Roberts, Chief Operating Officer and EVP. Source: SEC Form D, newest notice filed Mar 27, 2017. Read the notice at the SEC .
debt, options SEC Sep 2016 $6 M No. 3 $2 to $10 million 16
Cancer Genetics Inc.: Raise no. 3, Sep 2016 × Investors in this round 16 investors had bought by the notice of Dec 5, 2016: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cancer Genetics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions $385,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Edward J. Sitar · Executive Officer John A. Roberts · Executive Officer Panna L. Sharma · Executive Officer, Director Raju S.K. Chaganti · Executive Officer, Director Edmund L. Cannon · Director Franklyn G. Prendergast · Director Geoffrey J. Harris · Director Howard J. McLeod · Director John L. Pappajohn · Director Michael J. Welsh · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. WainWright & Co., LLC (CRD 375) · New York, New York Sold in CA, FL, IA, IL, MA, MD, MN, ND, NJ, NY, TX, WI Remarks in the notice On fees: “Excludes 137,500 placement agent warrants. Additionally, does not include additional compensation to placement agent re: tail fees pursuant to future transactions.”On the amounts: “Excludes proceeds totaling up to $3,093,750 from the exercise of the warrants.”On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”Signed by Edward J. Sitar, Chief Financial Officer. Source: SEC Form D, newest notice filed Dec 5, 2016. Read the notice at the SEC .
options SEC May 2016 $5 M No. 2 $2 to $10 million 41
Cancer Genetics Inc.: Raise no. 2, May 2016 × Investors in this round 41 investors had bought by the notice of May 25, 2016: 41 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cancer Genetics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions $350,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Edward J. Sitar · Executive Officer Panna L. Sharma · Executive Officer, Director Raju S.K. Chaganti · Executive Officer, Director Edmund L. Cannon · Director Franklyn G. Prendergast · Director Geoffrey J. Harris · Director Howard J. McLeod · Director John L. Pappajohn · Director Michael J. Welsh · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. WainWright & Co., LLC (CRD 375) · New York, New York Sold in CA, FL, IA, IL, MA, MD, MN, ND, NJ, NY, TX, WI Remarks in the notice On fees: “Excludes 123,391 placement agent warrants. Additionally, does not include additional compensation to placement agent re: tail fees pursuant to future transactions.”On the amounts: “Excludes proceeds totaling up to $2,776,297.50 from the exercise of the warrants.”On the use of proceeds: “Some of the proceeds may be used for general working capital purposes which may include the payment of salaries and other fees to those listed in Item 3.”Signed by Edward J. Sitar, Chief Financial Officer. Source: SEC Form D, newest notice filed May 25, 2016. Read the notice at the SEC .
options SEC Apr 2010 $7 M No. 1 $2 to $10 million 42
Cancer Genetics Inc.: Raise no. 1, Apr 2010 × Investors in this round 42 investors had bought by the notice of Nov 1, 2010: 42 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Cancer Genetics Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $10 M offered; $3 M still to sell
Smallest investment taken $10,000
What was sold equity
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions $6,620,620
Finders' fees none
Paid to its own people $460,000 (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Panna Sharma · Executive Officer, Director Raju Chaganti · Executive Officer, Director Andrew Pecora · Director Edmund Cannon · Director John Pappajohn · Director Riccardo Dalla-Favera · Director Tommy Thompson · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Allen Partners (CRD 36518) · broker-dealer Portfolio Advisors Alliance, Inc. (CRD 101680) · New York, New York Sold in AL, AZ, CA, CO, CT, DC, DE, FL, GA, HI, IA, IL, IN, KY, LA, MA, MD, ME, MI, MN, MO, MS, NC, NE, NH, NJ, NV, NY, OH, OK, OR, PA, PR, SC, TX, UT, VA, VT, WA, WI, WV, WY Felix Investments, LLC (CRD 148441) · New York, New York Sold in all US states Garden State Securities, Inc. (CRD 10083) · broker-dealer Portfolio Advisors Alliance, Inc. (CRD 101680) · Wall Township, New Jersey Sold in all US states Signed by Panna Sharma, President. Source: SEC Form D and 1 amendment, newest notice filed Nov 1, 2010. Read the notice at the SEC .
equity SEC